Keyword: Kalydeco

England’s National Health Service made its "final" offer to cover Vertex's cystic fibrosis drugs, but the company still isn't happy.

Vertex CEO Jeffrey Leiden took his fight over CF drug prices to U.K. Prime Minister Theresa May, urging her to step in.

Vertex has cancelled plans to test an investigational triple combo at several sites in France.

Vertex is ready to do some deals, CEO Jeffrey Leiden said Monday, and he's shopping beyond cystic fibrosis. CRISPR, for instance.

Stepped-up competition and insurer pushback aren't going away, but some are better able to handle it—and could emerge as top M&A targets.

Last year, the FDA nixed Vertex’s bid to expand Kalydeco to patients with specific mutations in the CFTR gene. On Wednesday, though, the drugmaker finally got what it wanted.

Vertex started tying compensation more closely to company performance last year, and it showed in CEO Jeff Leiden's 2016 pay.

Vertex has a new cystic fibrosis combo prospect it hopes can fare better than Orkambi—but the question is, how much?

Vertex is consolidating its R&D operations to three sites and shuttering one facility in Canada in a move that will claim 70 jobs there.